-

Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders

LAVAL, Quebec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today announced the voting results from its Annual General and Special Meeting of Shareholders held at its corporate headquarters in Laval, Quebec on June 5, 2024. The detailed results of the votes received by proxy are as follows:

Election of Directors

 

Director Nominees


NUMBER OF SHARES


PERCENTAGE OF VOTES CAST


FOR


WITHHELD


FOR


WITHHELD

Daniel N. Chicoine

6,490,732

109,026

98.3%

1.7%

Anthony E. Dobranowski

6,508,888

90,870

98.6%

1.4%

John C. London

6,533,190

66,568

99.0%

1.0%

Deborah Shannon-Trudeau

6,541,297

58,461

99.1%

0.9%

Serge Verreault

6,590,211

9,547

99.9%

0.1%

Reappointment of External Auditors

 

Outcome


NUMBER OF SHARES


PERCENTAGE OF VOTES CAST


FOR


WITHHELD


FOR


WITHHELD

Ernst & Young LLP reappointed

7,212,551

148,556

98.0%

2.0%

Approval of the Continuation of Crescita’s Share Incentive Plan

 

Outcome


NUMBER OF SHARES


PERCENTAGE OF VOTES CAST


FOR


AGAINST


FOR


AGAINST

Share Incentive Plan approved

6,526,477

73,281

98.9%

1.1%

About Crescita Therapeutics Inc.

Crescita (TSX: CTX and OTC US: CRRTF) is a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house R&D and manufacturing capabilities. The Company offers a portfolio of high-quality, science-based non-prescription skincare products and a commercial stage prescription product. We also own multiple proprietary transdermal delivery platforms that support the development of patented formulations to facilitate the delivery of active ingredients into or through the skin. For more information visit, www.crescitatherapeutics.com.

Source: Crescita Therapeutics

Contacts

Linda Kisa, CPA, CA
Vice-President, Reporting and Corporate Affairs
Email: lkisa@crescitatx.com

Industry:

Crescita Therapeutics

TSX:CTX
Release Versions
English

Contacts

Linda Kisa, CPA, CA
Vice-President, Reporting and Corporate Affairs
Email: lkisa@crescitatx.com

More News From Crescita Therapeutics

Crescita Therapeutics Inc. Announces Closing of Arrangement

LAVAL, Québec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”) is pleased to announce the closing of the previously announced plan of arrangement (the “Arrangement”) with ClinActiv Holdings Inc. (“ClinActiv”) and its wholly-owned subsidiary (the “Purchaser”), pursuant to which the Purchaser acquired all the issued and outstanding common shares of the Company (the “Shares”) in exchange for cash consideration of $0.80 per Share (the “Consider...

Crescita Therapeutics Inc. Announces Final Consideration Payable to Shareholders Pursuant to Arrangement with ClinActiv

LAVAL, Québec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”) is pleased to announce that holders of the issued and outstanding common shares (the “Shares”) of the Company (each a “Shareholder”) will be entitled to receive $0.80 per Share (subject to any applicable withholdings) (the “Consideration”) under its previously announced plan of arrangement (the “Arrangement”) with ClinActiv Holdings Inc. (“ClinActiv”) and its wholly-owned subsid...

Crescita Therapeutics Inc. Obtains Final Order Approving Plan of Arrangement

LAVAL, Québec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”) is pleased to announce that it has obtained a final court order from the Ontario Superior Court of Justice (Commercial List) approving its previously announced plan of arrangement (the “Arrangement”) with ClinActiv Holdings Inc. (“ClinActiv”) and its wholly-owned subsidiary (the “Purchaser”), pursuant to which the Purchaser will acquire all of the issued and outstanding common s...
Back to Newsroom